AbbVie Inc. vs Target Corporation: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Target Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Target Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Target Corporation is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $55.3B against $107.4B for Target Corporation, while their respective market capitalizations stand at $312.4B and $63.5B. AbbVie Inc. is headquartered in United States and Target Corporation operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

Target Corporation: Target is a retailer whose value comes from making mass retail feel curated. The business is strongest when stores, digital channels, owned brands and fulfillment services reinforce one another.

AbbVie Inc. and Target Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Target Corporation.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics. AbbVie's business model is structured around leveraging high-margin, blockbuster specialty medicines to fund expansive research and development and aggressive strategic acquisitions. For years, this model was overwhelmingly reliant on Humira, the world's best-selling drug. However, anticipating the inevitable loss of exclusivity, AbbVie proactively evolved its business model through diversification. Today, the model relies on a balanced portfolio strategy spanning immunology (Skyrizi and Rinvoq), hematologic oncology (Imbruvica and Venclexta), neuroscience (Vraylar and Qulipta), and aesthetics (Botox and Juvederm). This diversified approach mitigates the risk associated with patent cliffs and generic competition. the inclusion of the aesthetics portfolio provides an unique, largely cash-pay revenue stream that is less susceptible to traditional pharmaceutical pricing pressures and government reimbursement constraints. The company continually reinvests its significant cash flow into targeted acquisitions and clinical partnerships, ensuring a steady pipeline of next-generation therapies to sustain long-term revenue growth and support a robust dividend return strategy for investors. This strategic alignment ultimately provides significant resilience against unforeseen market disruptions and generic pressures. AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.

Target Corporation business model: Target runs a general-merchandise, big-box retail model that pairs low-margin essentials (groceries, household basics) to drive store traffic with higher-margin discretionary categories (apparel, home decor, and private-label brands) to drive profit -- the classic 'basket size' strategy. Owned and exclusive brands make up a large share of sales and carry better margins than national brands, a strategy Target has leaned on more heavily to compete with Walmart's scale and Amazon's convenience. Digital and same-day fulfillment, built around the 2017 Shipt (about $550 million) and Grand Junction acquisitions, let Target use its stores as fulfillment hubs -- a model that became central to growth during the pandemic and remains core to its omnichannel strategy today. FY2025 revenue was $104.780 billion, continuing a decline from $107.412 billion in fiscal 2023, as the company worked through a sales and stock slump serious enough to trigger a CEO change; Q1 FY2026 showed a rebound, with net sales growth of 6.7% and comparable sales up 5.6%. Target's owned-brand strategy, including labels like Good & Gather and Cat & Jack, has become an increasingly important profit lever as the retailer competes against both Walmart's scale and Amazon's convenience without matching either directly. Targets fiscal 2025 results reflected the ongoing challenge of balancing inventory discipline against the risk of stockouts during a demand recovery.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Target Corporation.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

Target Corporation competitive advantage: Target's advantage is the mix of curated merchandise, owned brands, convenient stores, same-day fulfillment and a brand position between discount utility and design-led retail.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Target Corporation each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

Target Corporation growth strategy: Target is focusing on merchandising authority, guest experience, technology acceleration, team and community strength, stores-as-hubs, same-day fulfillment, retail media and owned-brand renewal.

A closer look at the financial trajectory of AbbVie Inc. and Target Corporation rounds out the comparison.

AbbVie Inc.: AbbVie has executed one of the most successful pharmaceutical patent-cliff transitions in modern history. Following the loss of exclusivity for Humira (historically the world's best-selling drug), AbbVie's financial narrative in 2026 is defined by the explosive growth of its immunology successors, Skyrizi and Rinvoq. Under CEO Robert A. Michael, the company commands a $312.4 billion market cap and generates over $55.3 billion in revenue. AbbVie has utilized the cash flow from its aesthetics division (Botox) to fund aggressive M&A, including the multi-billion dollar acquisition of ImmunoGen to bolster its oncology pipeline with advanced antibody-drug conjugates (ADCs).

Target Corporation: Target is fighting a critical battle to restore traffic momentum and recapture the discretionary spending that migrated to Walmart and Amazon during the damaging inventory and brand perception crises of recent years. Under CEO Brian Cornell, the retail giant generated exactly $107.4 billion in revenue and maintains a $63.5 billion market cap with exactly 415000 employees. The financial narrative in 2026 is entirely defined by discretionary category reinvestment; rebuilding its coveted premium value reputation, Target extracts improving same-store sales by furiously expanding its differentiated owned brands, investing in store experience, and optimizing its same-day fulfillment through its beloved Drive Up and Shipt services.